Antcin K and NF-kB Inhibition

Antrodia Inflammation

4 disease models

Antcin K from Antrodia cinnamomea suppresses NF-kB signaling across rheumatoid arthritis, chondrosarcoma, periodontitis, and liver cancer cell models, with in vivo confirmation in collagen-induced arthritis mice.

Achudhan et al., Frontiers in Immunology, 2021

10-30 mg/kg

doses that reduced paw swelling in CIA mice

FAK/PI3K/Akt

upstream pathway converging on NF-kB

TNF-a, IL-1B, IL-8

cytokines suppressed in synovial fibroblasts

Achudhan et al., Frontiers in Immunology, 2021

View as image ↗

Nuclear factor-kB (NF-kB) is a transcription factor that sits at the center of inflammatory signaling in nearly every tissue. When activated, it drives the expression of cytokines, adhesion molecules, and matrix-degrading enzymes that sustain chronic inflammation. Antcin K, the most abundant ergostane triterpenoid in Antrodia cinnamomea fruiting bodies, suppresses NF-kB phosphorylation across at least four disease models: rheumatoid arthritis, chondrosarcoma, periodontitis, and hepatocellular carcinoma.^[1][2]

The convergence is striking. Different research groups, studying different diseases in different cell types, keep finding that antcin K shuts down the same signaling node. This article maps what those groups found and where the evidence stands. For a broader profile of antcin K's non-inflammatory activities (antidiabetic, hepatoprotective, anticancer), see antcin A, B, C, and K: individual compound research.

NF-kB: why this pathway matters

NF-kB is not one protein but a family of transcription factors (p65/RelA, p50, RelB, c-Rel, p52) that form dimers and bind DNA promoter regions. In the canonical pathway, NF-kB sits in the cytoplasm bound to its inhibitor IkB. When inflammatory signals (TNF-a, IL-1, lipopolysaccharide) activate upstream kinases, IkB gets phosphorylated and degraded, freeing NF-kB to enter the nucleus and switch on hundreds of pro-inflammatory genes.

Chronic NF-kB activation drives disease in rheumatoid arthritis (synovial inflammation and joint destruction), cancer (tumor survival, angiogenesis, metastasis), periodontal disease (gum tissue destruction), and metabolic disorders. The pathway is not binary. Low-level, transient NF-kB activation is essential for normal immune defense against pathogens. The pathological state is sustained, dysregulated activation that keeps inflammatory genes switched on continuously.

Pharmaceutical NF-kB inhibitors exist but tend to suppress immune function broadly, causing susceptibility to infections and impaired wound healing. Corticosteroids, for example, partially work through NF-kB suppression but carry well-documented long-term side effects. The interest in natural NF-kB modulators like antcin K comes from the possibility of more selective or tolerable suppression, though whether that selectivity exists in practice is unproven.

Rheumatoid arthritis: the most developed evidence

The strongest antcin K/NF-kB dataset comes from a series of studies on rheumatoid arthritis synovial fibroblasts (RASFs), the cells that line the joint capsule and drive RA inflammation.

Cytokine suppression through FAK/PI3K/Akt/NF-kB

Achudhan et al. (2021) published the first direct demonstration that antcin K inhibits NF-kB in RASFs. Treatment reduced the phosphorylation of four signaling proteins in sequence: focal adhesion kinase (FAK), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and NF-kB itself.^[1]

The downstream effect was suppression of three cytokines central to RA inflammation: TNF-a, IL-1B, and IL-8. These are not minor players. TNF-a is the primary therapeutic target of adalimumab, infliximab, and etanercept (biologics that generate billions in annual revenue). IL-1B drives cartilage degradation. IL-8 recruits neutrophils to the joint space.^[1]

The in vivo data strengthened the case. Intraperitoneal injections of antcin K at 10 mg/kg and 30 mg/kg in collagen-induced arthritis (CIA) mice produced measurable effects: reduced paw swelling, less cartilage degradation, less bone erosion, and decreased serum levels of TNF-a, IL-1B, IL-8, and IL-6.^[1] CIA is the standard mouse model for RA and the results represent the only in vivo demonstration of antcin K's anti-inflammatory activity in any disease context.

VCAM-1 and monocyte recruitment

A follow-up study from the same research group examined a different arm of RA pathology: immune cell recruitment to the inflamed joint. Achudhan et al. (2022) found that antcin K dose-dependently inhibited VCAM-1 (vascular cell adhesion molecule-1) expression in RASFs and reduced monocyte adhesion to these cells.^[3]

VCAM-1 sits on the surface of activated synovial fibroblasts and acts as a docking point for circulating monocytes. When monocytes adhere and infiltrate the joint, they differentiate into macrophages and osteoclasts that destroy cartilage and bone. Blocking VCAM-1 reduces this destructive recruitment.

The mechanism here was different from the NF-kB pathway in the cytokine study. Antcin K inhibited VCAM-1 through MEK1/2-ERK, p38, and AP-1 signaling cascades, not the FAK/PI3K/Akt/NF-kB axis.^[3] This suggests antcin K acts on multiple inflammatory signaling pathways simultaneously, not just NF-kB alone. In CIA mice, antcin K also reduced VCAM-1 and CD11b (a monocyte marker) expression in ankle tissue.^[3]

Anti-angiogenic activity

RA joints develop abnormal blood vessel growth (angiogenesis) that feeds the inflamed synovium and sustains disease activity. Achudhan et al. (2022) found that antcin K suppressed VEGF expression in RASFs and inhibited endothelial progenitor cell migration and tube formation through the phospholipase C-gamma/protein kinase C-alpha (PLCgamma/PKCalpha) pathway.^[4]

GEO database analysis confirmed higher VEGF levels in RA synovial tissue compared to osteoarthritis and healthy controls, and CIA mice showed elevated VEGF that antcin K reduced.^[4]

Taken together, the RA studies demonstrate antcin K targeting three interconnected aspects of joint inflammation: cytokine production (via NF-kB), immune cell recruitment (via VCAM-1), and blood vessel growth (via VEGF). For how antcin K operates in cancer contexts, see antcin anti-cancer activity: preclinical research.

Chondrosarcoma: NF-kB in bone cancer metastasis

Law et al. (2025) extended the NF-kB story into bone cancer. Chondrosarcoma, the second most common primary bone cancer, has limited treatment options once it metastasizes. Antcin K reduced migration and invasion in two chondrosarcoma cell lines.^[2]

RNA sequencing identified MMP-7 (matrix metalloproteinase-7) as the key downstream target. When the researchers overexpressed MMP-7, it reversed antcin K's anti-migratory effects, confirming MMP-7 suppression as the operative mechanism rather than a bystander change.^[2]

The upstream pathway was PI3K/Akt/mTOR/NF-kB. Antcin K abolished phosphorylation at each node in this cascade, which reduced NF-kB-driven MMP-7 transcription.^[2] This is the same FAK/PI3K/Akt/NF-kB axis found in the RA studies, extended by the addition of mTOR as an intermediate node.

The convergence between RA and cancer makes biological sense. Both diseases involve tissue invasion through matrix metalloproteinase activity, and both use NF-kB to regulate that activity. In RA, synovial fibroblasts invade cartilage using MMPs. In chondrosarcoma, tumor cells invade surrounding tissue and metastasize to the lungs using MMPs. Antcin K appears to intervene at the same signaling point in both contexts, reducing MMP expression by blocking the upstream PI3K/Akt/NF-kB cascade that drives MMP transcription.

Hepatoma: integrin-mediated metastasis

Huang et al. (2015) demonstrated that antcin K suppressed adhesion, migration, and invasion of Hep 3B hepatoma cells within 24 hours. The mechanism involved reduced expression of integrins beta-1, beta-3, alpha-5, and alpha-v, with downstream suppression of FAK, Src, PI3K, AKT, MEK, ERK, and JNK phosphorylation.^[5]

While this study did not explicitly measure NF-kB phosphorylation, the FAK/PI3K/Akt cascade it identified feeds directly into NF-kB activation. The integrin suppression, MMP-2 and MMP-9 reduction, E-cadherin upregulation, and vimentin downregulation reported by Huang et al. are all consistent with NF-kB pathway suppression.^[5]

Separately, Lai et al. (2016) showed antcin K induced apoptosis in Hep 3B cells through ROS generation, ER stress, and mitochondrial membrane collapse.^[6] This mechanism is distinct from NF-kB suppression. The apoptotic cascade proceeded through ATP depletion, endoplasmic reticulum stress, mitochondrial membrane permeability changes, and caspase-9/caspase-3 activation leading to PARP cleavage. The mode of death was confirmed as apoptosis (phosphatidylserine exposure present) rather than autophagy or necrosis.^[6]

The existence of both NF-kB-dependent (anti-metastatic) and NF-kB-independent (pro-apoptotic) mechanisms in the same cell type suggests antcin K has multiple molecular targets in liver cancer, though whether these interact or operate in parallel has not been tested.

The pathway map: FAK to NF-kB

Across studies, a consistent signaling architecture emerges:

Step 1: Integrin/FAK suppression. Antcin K reduces integrin expression on cell surfaces, which decreases FAK phosphorylation. FAK is a kinase that sits at focal adhesion complexes where cells attach to extracellular matrix.

Step 2: PI3K/Akt inhibition. FAK activates PI3K, which phosphorylates Akt. Antcin K reduces phosphorylation at both nodes.

Step 3: NF-kB suppression. Akt activates IKK (IkB kinase), which phosphorylates IkB for degradation, freeing NF-kB. By reducing Akt activity, antcin K keeps IkB intact and NF-kB sequestered in the cytoplasm.

Step 4: Downstream gene silencing. With NF-kB inactive, transcription of TNF-a, IL-1B, IL-8, VCAM-1, MMP-7, and other inflammatory/invasive genes drops.

This is not a single-study model. It is reconstructed from five independent studies using different cell types (synovial fibroblasts, chondrosarcoma cells, hepatoma cells) from different laboratories.^[1][2][5]

Antcin K also acts through NF-kB-independent pathways. The VCAM-1 study used MEK/ERK/AP-1 signaling. The VEGF study used PLCgamma/PKCalpha. The hepatoma apoptosis study used ER stress and mitochondrial pathways. NF-kB inhibition is the most consistent thread, but antcin K is not a single-target compound.

What remains unknown

Oral bioavailability is uncharacterized. The CIA mouse studies used intraperitoneal injection, bypassing the gut. Whether oral antcin K reaches effective tissue concentrations is unknown.

Dose-response relationships are incomplete. The two doses tested in vivo (10 and 30 mg/kg) both showed effects, but the minimum effective dose, maximum tolerated dose, and therapeutic window have not been defined.

Specificity vs. breadth. Antcin K's multi-pathway activity (NF-kB, AP-1, PLCgamma, ER stress) could be an advantage or a concern. Broad suppression of inflammatory signaling risks immunosuppression, the same problem that limits pharmaceutical NF-kB inhibitors.

No human pharmacokinetic or safety data exist. All studies are in cell culture or mouse models. The authors of the 2021 study stated their data "support clinical investigations," but no such investigations have been reported.

Source variation. Antcin K content varies with Antrodia cinnamomea cultivation method. Basswood-cultivated fruiting bodies produce the highest antcin K concentrations, while submerged fermentation mycelia produce substantially less. Standardization across commercial preparations is absent, meaning two Antrodia supplements could contain vastly different antcin K levels.

Interaction with existing drugs. Many RA patients take methotrexate, biologics, or JAK inhibitors. Whether antcin K potentiates, antagonizes, or interacts with any of these has not been investigated. The overlapping mechanism (NF-kB suppression) raises the theoretical risk of excessive immunosuppression if combined with existing anti-inflammatory therapies.

Limited research groups. Much of the antcin K/NF-kB literature comes from a single research network centered on Chih-Hsin Tang's laboratory in Taiwan. Independent replication by other groups would strengthen confidence in the findings. For how antcins differ across sibling compounds, see antrodia and inflammation: anti-inflammatory triterpenoid research.

The Bottom Line

Antcin K from Antrodia cinnamomea consistently suppresses NF-kB signaling across rheumatoid arthritis, bone cancer, and liver cancer cell models. The best evidence comes from RA research, where antcin K reduced cytokine production, monocyte recruitment, and angiogenesis in synovial fibroblasts and attenuated disease in collagen-induced arthritis mice at 10-30 mg/kg. The FAK/PI3K/Akt/NF-kB axis appears to be the primary signaling route, though antcin K acts on additional pathways. All data remains preclinical with no human trials.

Frequently Asked Questions

What does antcin K do to NF-kB?

Antcin K reduces phosphorylation of NF-kB by suppressing its upstream activators FAK, PI3K, and Akt. With less Akt activity, IkB (the inhibitor that holds NF-kB in the cytoplasm) stays intact, preventing NF-kB from entering the nucleus and switching on inflammatory genes. This has been demonstrated in rheumatoid arthritis synovial fibroblasts (Achudhan et al., 2021) and chondrosarcoma cells (Law et al., 2025).

Can antcin K treat rheumatoid arthritis?

In preclinical models, antcin K showed anti-arthritic effects. Intraperitoneal injections at 10 and 30 mg/kg reduced paw swelling, cartilage damage, bone erosion, and serum cytokine levels in collagen-induced arthritis mice (Achudhan et al., 2021). No human trials have tested antcin K for rheumatoid arthritis or any other inflammatory condition.

Where does antcin K come from?

Antcin K is an ergostane-type triterpenoid extracted from Antrodia cinnamomea (also called Antrodia camphorata), a medicinal mushroom that grows exclusively on Cinnamomum kanehirae trees in Taiwan. It is the most abundant triterpenoid in basswood-cultivated fruiting bodies. Wild Antrodia is extremely rare and expensive; most research uses cultivated material.

Is antcin K anti-inflammatory?

In cell culture and animal models, antcin K suppresses multiple inflammatory mediators. It reduced TNF-alpha, IL-1beta, IL-8, and IL-6 in rheumatoid arthritis synovial fibroblasts and collagen-induced arthritis mice (Achudhan et al., 2021). It also inhibited VCAM-1-dependent monocyte adhesion (Achudhan et al., 2022) and VEGF-driven angiogenesis (Achudhan et al., 2022). These are preclinical findings only.

How does antcin K compare to anti-TNF drugs?

Antcin K suppresses TNF-alpha expression in synovial fibroblasts, which is the same cytokine targeted by biologic drugs like adalimumab and infliximab. However, biologics directly neutralize circulating TNF-alpha protein, while antcin K reduces TNF-alpha gene transcription through upstream NF-kB pathway suppression. No head-to-head comparison exists, and antcin K has not been tested in humans.

Does antcin K have side effects?

No human safety data exists for antcin K. In cell culture studies, antcin K did not show cytotoxicity at anti-inflammatory concentrations in rheumatoid arthritis synovial fibroblasts (Achudhan et al., 2022). In CIA mice, intraperitoneal doses up to 30 mg/kg were tolerated without reported adverse effects (Achudhan et al., 2021). These limited preclinical observations cannot predict human safety.

Sources & References

1. 1RTHM-00670·Achudhan, David et al. (2021). “Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis..” Frontiers in immunology.Study breakdown →PubMed →↩
2. 2RTHM-00935·Law, Yat-Yin et al. (2025). “Antcin K inhibits chondrosarcoma motility by reducing MMP‑7 expression via downregulation of the PI3K, Akt, mTOR and NF‑κB signaling pathway..” Molecular medicine reports.Study breakdown →PubMed →↩
3. 3RTHM-00738·Achudhan, David et al. (2022). “Antcin K inhibits VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts..” Food & nutrition research.Study breakdown →PubMed →↩
4. 4RTHM-00739·Achudhan, David et al. (2022). “Antcin K inhibits VEGF-dependent angiogenesis in human rheumatoid arthritis synovial fibroblasts..” Journal of food biochemistry.Study breakdown →PubMed →↩
5. 5RTHM-00377·Huang, Ya-Ling et al. (2015). “Antcin K, an Active Triterpenoid from the Fruiting Bodies of Basswood-Cultivated Antrodia cinnamomea, Inhibits Metastasis via Suppression of Integrin-Mediated Adhesion, Migration, and Invasion in Human Hepatoma Cells..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
6. 6RTHM-00432·Lai, Chiao-I et al. (2016). “Antcin K, an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces mitochondria and endoplasmic reticulum stress-mediated apoptosis in human hepatoma cells..” Journal of traditional and complementary medicine.Study breakdown →PubMed →↩